Effects of TBC169 on gut microbiota and metabolites in gynecological laparoscopy patients.

OBJECTIVE

The primary objective of this study is to investigate the mechanism by which TBC169 accelerates intestinal function recovery in patients who have undergone gynecological laparoscopic surgery, using metabolomics and gut microbiota analysis.

METHODS

A total of 20 subjects were selected and randomly divided into two groups: the intervention group ( = 10) receiving TBC169 Tablets (6 pills, 1.05 × 10 CFU), and the control group ( = 10) receiving placebos (6 pills). After the initial postoperative defecation, fecal samples were collected from each subject to analyze their gut microbiota and metabolic profiles by high-throughput rRNA gene sequencing analysis and untargeted metabonomic.

RESULTS

There were no statistically significant differences observed in the α-diversity and β-diversity between the two groups; however, in the intervention group, there was a significant reduction in the relative abundance of at the genus level. Furthermore, the control group showed increased levels of and , whereas the intervention group exhibited elevated levels of . And administration of TBC169 led to variations in 2 metabolic pathways: D-glutamine and D-glutamate metabolism, and arginine biosynthesis.

CONCLUSION

This study demonstrated that consuming TBC169 after gynecological laparoscopic surgery might inhibit the proliferation of harmful ; mainly influence 2 pathways including D-glutamine and D-glutamate metabolism, and arginine biosynthesis; and regulate metabolites related to immunity and intestinal motility; which can help regulate immune function, maintain intestinal balance, promote intestinal peristalsis, and thus accelerate the recovery of intestinal function.